Promega Receives SBTi Validation for Near-Term Emissions Reduction Targets

Promega Corporation has received formal validation from the Science Based Targets initiative (SBTi) for its near-term greenhouse gas emission reduction goals. According to the company, these targets include a 47% reduction in Scope 1 and 2 emissions and a 42% reduction in Scope 3 emissions by 2030, based on a 2023 baseline. This move aligns the biotechnology firm with global standards designed to mitigate the most severe impacts of climate change.

How do science-based targets change corporate sustainability?

Science-based targets provide a standardized framework for companies to align their decarbonization efforts with the Paris Agreement. According to the SBTi, this organization develops the criteria and validation protocols necessary to ensure corporate climate action is grounded in empirical climate science rather than voluntary, unverified pledges.

By securing this validation, Promega moves beyond internal reporting. Corey Meek, head of corporate responsibility at Promega, states that the validated goals function as a verified roadmap that integrates third-party accountability into the company’s environmental strategy. For the biotechnology industry, this provides a transparent benchmark that allows clients and supply chain partners to assess carbon footprints with greater confidence.

What are the specific reduction goals for 2030?

Promega has committed to three primary categories of emissions reduction to be achieved by 2030:

• Scope 1 and 2: A 47% absolute reduction in emissions from direct operations and purchased electricity, using 2023 as the base year.
• Scope 3 (Absolute): A 42% absolute reduction in supply chain emissions, specifically targeting capital goods and business travel.
• Supplier Engagement: A commitment to ensure 67% of suppliers—measured by spend on purchased goods and upstream transport—set their own SBTi-aligned reduction targets.

Pro Tip: When evaluating a company’s climate commitment, look for "Scope 3" targets. These are often the most difficult to achieve because they require a company to influence the behavior of their entire supply chain, rather than just controlling their own facilities.

Why is Scope 3 the new focus for biotech procurement?

The biotechnology sector is increasingly prioritizing Scope 3 emissions because they represent the largest portion of a typical firm’s carbon impact. According to industry data, procurement teams are now using third-party validations like those from the SBTi to simplify vendor compliance.

While Promega has already achieved 100% renewable electricity for its global operations—addressing the bulk of its Scope 2 footprint—the focus is now shifting to the broader value chain. By requiring suppliers to commit to science-based targets, Promega is essentially creating a ripple effect, pushing smaller manufacturers and logistics providers to decarbonize to remain competitive in the pharmaceutical supply chain.

Did you know?

The SBTi classifies emissions into three tiers: Scope 1 covers direct emissions from owned sources (like onsite fuel combustion), Scope 2 covers indirect emissions from purchased energy, and Scope 3 accounts for all other indirect emissions, including the entire life cycle of purchased goods and services.

Frequently Asked Questions

What does it mean for a target to be "science-based"?
It means the reduction goals are consistent with the level of decarbonization required to keep global temperature increases below the thresholds set by the scientific community to avoid catastrophic climate change.

Has Promega already started reducing its emissions?
Yes. The company reports it has already transitioned to 100% renewable electricity across its global operations, which serves as a foundation for meeting its Scope 1 and 2 targets.

Why is supplier engagement critical to these goals?
Because a significant portion of a company’s carbon footprint exists within its supply chain (Scope 3). By mandating that 67% of suppliers adopt science-based targets, Promega ensures that emissions reductions are occurring upstream, not just at their own facilities.

Where can I track the company’s progress?
Promega provides updates on its environmental, social, and governance (ESG) efforts through its official corporate responsibility portal.

Are you interested in how sustainability standards are reshaping the biotech industry? Leave a comment below or subscribe to our newsletter for updates on corporate climate accountability.